Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
Public ClinicalTrials.gov record NCT04037605. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to 1) determine how hypothalamic-pituitary-adrenal axis (HPA axis) activation occurs with sleep restriction and 2) evaluate how hypothalamic-pituitary-gonadal axis (HPG axis) deactivation occurs with sleep restriction. The investigator will also examine the cognitive function associated with sleep restriction, including food intake and food cravings.
Study identification
- NCT ID
- NCT04037605
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 5 participants
Conditions and interventions
Conditions
Interventions
- Ketoconazole Pill (also known as nizoral) Drug
- Ganirelix Drug
- Dexamethasone Pill Drug
- Dexamethasone injection Drug
- Cosyntropin Injectable Product Drug
- Recombinant Human Luteinizing Hormone (also known as luveris) Drug
- Hydrocortisone Injection (also known as solu-cortef) Drug
- Gonadorelin (also known as Lutrepulse) Drug
- Corticorelin (also known as Acthrel) Drug
- Placebo oral tablet Drug
- Saline Solution Drug
- Saline solution for injection Drug
Drug
Eligibility (public fields only)
- Age range
- 60 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 8, 2020
- Primary completion
- Jul 23, 2022
- Completion
- Jun 23, 2026
- Last update posted
- Sep 10, 2025
2020 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Los Angeles Biomedical Research Institute | Torrance | California | 90509 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04037605, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04037605 live on ClinicalTrials.gov.